Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review

Overview of attention for article published in Frontiers in immunology, February 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 3 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 54,144 followers.

Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: … https://t.co/gJt8U7WcqB https://t.co/wpMKFwuSwd

13 Mar 2023

Reply Repost Favourite

#NOVARTIS Entra de Frente en la Carrera de Posibles Tratamientos Contra el #Cáncer_Pulmón_Microcítico . La Combinación de #Inmunoterapia (#TISLELIZUMAB By NOVARTIS) Más #Quimioterapia (#ETOPÓSIDO - #CARBOPLATIN) Ha Conseguido Una Respuesta Completa . https

02 Mar 2023

Reply Repost Favourite

Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review https://t.co/hC3s4ZoclS https://t.co/QB1ABim7V8

01 Mar 2023

Reply Repost Favourite

New Research: Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review: Immunotherapy plus chemotherapy has been approved for the first-line… https://t.co/MpJQDmG

23 Feb 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.